The Awakening of the Narcolepsy Landscape

Released On
September 2, 2021

Expires On
September 2, 2022

Media Type

Completion Time
60 minutes

Neurology, Primary Care, Sleep Medicine

Sleep Medicine

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Paradigm Medical Communications, LLC . In collaboration with Project Sleep.


This activity is supported by educational grants from Avadel CNS Pharmaceuticals, LLC and Harmony Biosciences, LLC.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to address the educational needs of sleep medicine specialists. It may also benefit primary care physicians and other clinicians who are interested or involved in the care of patients with narcolepsy.

Statement of Need

Patients with narcolepsy average 10 years between symptom onset and diagnosis. All the while, sufferers try, in vain, to navigate the hallmark symptom of excessive daytime sleepiness (EDS)—with or without cataplexy—that can disrupt their careers, relationships, social lives, and overall functionality. Even with treatment, few patients with narcolepsy achieve sufficient control of their symptoms, or symptoms are improved at the cost of adverse events. Fortunately, the narcolepsy treatment landscape has recently expanded to include novel and unscheduled agents that offer advantages of efficacy, safety, and/or convenience over many conventional agents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Distinguish narcolepsy from mimickers and comorbidities via comprehensive evaluation and testing
  • Differentiate novel narcolepsy treatments based on their proposed mechanisms of action (MOAs)
  • Formulate an individualized, symptom-based narcolepsy treatment plan that aligns with clinical trial data and patients’ needs and preferences


Margaret Park, MD

Chicago Sleep Health
Chicago, IL

Asim Roy, MD

Medical Director
Ohio Sleep Medicine Institute
Dublin, OH

Patient Faculty
Julie Flygare, JD

President & CEO
Project Sleep
Los Angeles, CA

Accreditation Statement

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education

PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosures of Conflicts of Interest

In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been mitigated.

Margaret Park, MD

  • Speakers Bureau: Eisai, Inc; Harmony Biosciences, LLC

Asim Roy, MD

  • Consulting Fees: Avadel CNS Pharmaceuticals, LLC; Jazz Pharmaceuticals, Inc.
  • Speakers Bureau: Eisai, Inc; Harmony Biosciences, LLC.; Inspire Pharma; Jazz Pharmaceuticals, Inc
  • Grant/Research Support: Avadel CNS Pharmaceuticals, LLC; Jazz Pharmaceuticals, Inc, Nyxoah

Patient Faculty
Julie Flygare, JD

  • Consulting Fees: Avadel CNS Pharmaceuticals, LLC; Jazz Pharmaceuticals, Inc; Takeda Pharmaceutical Company Ltd

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.
Patient reviewer has no financial relationships to disclose.

Instructions for Participation and Credit

To receive a CME certificate of participation, you should:

  1. Follow instructions to register or log in with your professional information and complete the pre-activity assessment
  2. View the online activity in its entirety
  3. Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or

There is no fee required for participation in this activity.

Course Viewing Requirements

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here:

Technical Support:
If you have any technical problems or playback issues email us at

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.


This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Contact Information

Contact Us
If you have any questions or comments, please email us at